MilliporeSigma has opened a facility in Mollet des Vallès, Spain dedicated to the manufacture of meglumine, an FDA-approved excipient for pharmaceuticals and a component of medical imaging contrast media.  
 
The facility has been validated by the FDA and is currently the only location in Europe that manufactures meglumine, an amino sugar derived from glucose. As an excipient, meglumine interacts directly with active pharmaceutical ingredients to increase solubility and therefore must meet the same stringent regulatory and quality requirements as APIs.
 
“Our new facility was optimized around the manufacturing process to achieve greater efficiencies and meets the most stringent quality standards for manufacturing meglumine,” said Andrew Bulpin, head of Process Solutions Strategic Marketing & Innovation, MilliporeSigma. “The result is a high level of confidence in quality and security of supply for our customers.”